About us

Arquer Diagnostics Ltd

  • Arquer Diagnostics (Arquer) is a private, UK-based diagnostics company focused on the development and commercialisation of non-invasive immunoassay diagnostic tests for cancer diagnosis and monitoring.
  • Arquer’s tests are based on minichromosome maintenance (MCM) proteins, markers for the presence of dividing cancer cells. This patent protected, intellectual property is licensed exclusively from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK.

Taking ground breaking research…

  • MCM protein biomarkers have been the subject of cancer research for 20 years since they were first demonstrated at Cambridge University over 20 years ago by Prof. R Laskey and Prof. K Stoeber1-4.

…Developing it…

  • Dr Nick Miller-Jones (Cambridge Scientist), developed the Arquer prototype MCM5 ELISA in collaboration with Cancer Research UK.
  • That prototype has been perfected and tested extensively by the Arquer Team at our base in Sunderland (North-East, UK) and is undergoing clinical trials and further testing in a number of cancer types across the UK, Europe and the USA.

…and commercialising clinically relevant tests

  • ADXBLADDER is the first of Arquer’s MCM5 tests to be released as a CE IVD test and is available to urologists and laboratories through a growing network of distributors.